Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sparkle: ARGX-119 in Pediatric Spinal Muscular Atrophy
NCT07287982Phase 2Recruiting
- Sponsor
- argenx
- Start
- Dec 2025
- Primary completion
- May 2029
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of adimanebart in spinal muscular atrophy (SMA) (3 arms), sponsored by argenx. Primary endpoints: Incidence of Adverse Events at 124 weeks, Incidence of Serious Adverse Events at 124 weeks and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
adimanebart
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT07287982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287982.